@article{article_1618269, title={The Long-Term Effects on Recurrence and Progression of Bladder Tumors of Chemotherapeutic Agents Used After Transurethral Resection}, journal={Endoüroloji Bülteni}, volume={17}, pages={61–70}, year={2025}, DOI={10.54233/endourolbull-1618269}, author={Kıraç, Emre and Korğalı, Esat and Saygın, Hüseyin and Asdemir, Aydemir and Ergin, İsmail Emre and Öztürk, Abuzer and Kır, Adem and Velibeyoğlu, Arslan Fatih}, keywords={Mesane kanseri, Nüks, Progresyon, Epirubisin, Gemcitabin}, abstract={Objective: Early single dose chemotherapy may have a reducing effect on recurrence and progression. In this study, we aimed to compare non-muscle invasive patients diagnosed with bladder cancer who did not receive early single dose chemotherapy and those who received intravesical Epirubicin or Gemcitabine in terms of recurrence and progression.
Material and Methods: 116 patients were followed up for 48 months (May 2020-June 2022) with diagnosis of primary non-invasive bladder cancer. After transurethral resection of the bladder, patients were followed up with 3 groups: who received intravesical epirubicin, who received gemcitabine, who did not receive any chemotherapeutic agent.
Results: The mean age was 63. There were no statistically significant difference in age and, body mass index. Recurrence was determined 57.1% (n=20), 40% (n=18), and 41.7% (n=15) (p=0.263) of the patients, respectively who were not administered any intravesical agent, were administered Epirubicin and, Gemcitabine. While recurrence rates were observed 50%, 25%, 0% (p=0.177) respectively, in low-risk, no progression was detected. In intermediate risk group, 66.7%, 33.3%, 42.8% (p=0.378) recurrence, and 33.3%, 22.7%, 6.7% (p=0.282) progression were detected, respectively. High-risk group, recurrence was found in 56%, 64.2%, 56.2% (p=0.866) of the patients and progression 8%, 14.3%, 6.3% (p=0.723) respectively. In low-grade group, 35.7%, 42.9%, 21.4% (p=0.045) recurrence, and 16.6%, 12.1%, and 4.3% (p=0.164) progression were determined , respectively. In the high-grade group, 58.8%, 50%, 69.2% (p=0.982) recurrence, 5.9%, 16.6% and 7.7% (p=0.581) progression were detected, respectively. Conclusion: These findings demonstrated that intravesical chemotherapeutics can delay or prevent recurrence and progression, should therefore be administered in early postoperative period. Gemcitabine is not in widespread use and has been found to be a good alternative.}, number={2}, publisher={Endoüroloji Derneği}, organization={No financial support was received.}